Publications by authors named "V Leblond"

Claim this Profile
L
Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia.
Véronique Leblond, Jean-Richard Eveillard, Driss Chaoui, Doriane Cavalieri, Caroline Dartigeas

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.
Damien Roos-Weil, Cécile Tomowiak, Stéphanie Poulain, Florence Nguyen-Khac, Florian Bouclet, Véronique Leblond

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenotypic Profile of Waldenström Macroglobulinaemia B-Cells: Establishment of a Diagnosis Scoring System and Clinico-Biological Correlations.
Elise Sourdeau, Clémentine Boccon-Gibod, Aurélien Corneau, Myrto Costopoulos, Clotilde Bravetti, Véronique Leblond

J Cell Mol Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers.
Aurelie Drouin, Laurine Durand, Clara Esnault, Pauline Gaboriaud, Valérie Leblond

J Immunother Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.
Benjamin M Heyman, Stephen S Opat, Björn E Wahlin, Meletios-Athanasios C Dimopoulos, Jorge J Castillo, Véronique Leblond

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis